The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide

We have dissected the role of Estrogen receptor beta (ERβ) in prostate cancer (PCa) with a novel ERβ ligand, OSU-ERb-12. Drug screens revealed additive interactions between OSU-ERB-12 and either epigenetic inhibitors or the androgen receptor antagonist, Enzalutamide (Enza). Clonogenic and cell biolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Jaimie S., Wani, Sajad A., Hussain, Shahid, Huang, Phoebe, Nayak, Debasis, Long, Mark D., Yates, Clayton, Clinton, Steven K., Bennet, Chad E., Coss, Christopher C., Campbell, Moray J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680693/
https://www.ncbi.nlm.nih.gov/pubmed/38014010
http://dx.doi.org/10.1101/2023.11.15.567282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680693/
https://www.ncbi.nlm.nih.gov/pubmed/38014010
http://dx.doi.org/10.1101/2023.11.15.567282

Ejemplares similares